Trials / Recruiting
RecruitingNCT07150845
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Evommune, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EVO756 | Dose 1 |
| DRUG | EVO756 | Dose 2 |
| DRUG | EVO756 | Dose 3 |
| DRUG | Placebo control | Placebo control |
Timeline
- Start date
- 2025-08-26
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2025-09-02
- Last updated
- 2025-12-16
Locations
25 sites across 2 countries: United States, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07150845. Inclusion in this directory is not an endorsement.